Q-omics provides the consensus-scored NPY4R profile across patient tissues and cancer cell-line models. NPY4R expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, NPY4R is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, NPY4R RNA expression shows 11,663 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, KIRC, and TGCT as cancer lineages where NPY4R shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPY4R — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPY4R survival associations across molecular data types. NPY4R RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPY4R RNA expression–survival associations across cancer types. High NPY4R expression shows unfavorable associations in DLBC, KIRC, UCEC and KICH, but favorable associations in ACC and ESCA. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify DLBC as the clearest survival context for NPY4R RNA expression.
This table summarizes NPY4R tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NPY4R. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPY4R shows lower tumor expression in LUSC, LUAD, READ and BRCA and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher NPY4R RNA expression in tumor versus normal tissue (log2 FC = +0.147, t-test p < 0.001).
This table shows molecular features associated with NPY4R in patient tissues and cancer cell lines. In patient samples, NPY4R shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NPY4R RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
